Incontinence News and Research

Latest Incontinence News and Research

AMS’ products restore patient's pelvic health and their quality of life

American Medical Systems® (AMS), a leading provider of world-class devices and therapies for both male and female pelvic health, today announced the results of three major clinical studies that each point to a high degree of efficacy and patient satisfaction with AMS’ minimally invasive treatment options for female stress urinary incontinence (SUI) and vaginal prolapse.

30 Sep 2009

Effective decision support tools may help decide whether or not to undertake PSA screening

Although screening for prostate cancer with the Prostate Specific Antigen (PSA) test in men ages 50-70 can detect the cancer before it becomes symptomatic, knowing whether screening is beneficial for these men is uncertain.

30 Sep 2009

Urodynamix closes $1.5 million non-brokered private placement for common shares

Urodynamix Technologies Ltd. (TSX VENTURE:URO) is pleased to announce that it has closed a $1.5 million non-brokered private placement for 30,000,000 common shares previously reported on September 11, 2009.

29 Sep 2009

Quintiles Transnational enter into marketing agreement with Allergan for SANCTURA XR

Quintiles Transnational Corp. and Allergan, Inc. (NYSE: AGN) today announced an agreement under which Quintiles will co-promote Allergan's SANCTURA XR® (trospium chloride extended release capsules), an anticholinergic approved for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency, predominantly to primary care physicians in the United States.

28 Sep 2009

Initial clinical results for Mpathy Medical's Omnisure sling released

Mpathy Medical, a rapidly growing medical device company which has developed and brought to market a range of less invasive surgical solutions used to restore pelvic health to women, released the initial clinical results for its newest product, Omnisure™, a novel full length sling for treatment of female stress urinary incontinence (SUI) at the American Urogynecologic Society’s (AUGS) Annual Meeting.

26 Sep 2009

NHSSC awards contract to AMS to supply SUI treatment devices in UK

American Medical Systems (AMS), a leading provider of world-class devices and therapies for both male and female pelvic health, announced today that it has been included as part of a multiple-awardees contract by National Healthcare Services (NHS) Supply Chain (NHSSC) to supply three of its clinically-proven female stress urinary incontinence (SUI) treatment devices through the Normanton distribution centre, United Kingdom.

24 Sep 2009

Study compares benefits of laparoscopic and traditional open surgery for prostate cancer

The more things change, the more they stay the same, as the proverb goes. A study appearing in an upcoming edition of The Journal of Oncology appears to prove just that. The study compares the benefits of laparoscopic surgery versus traditional open surgery in the treatment of prostate cancer. With traditional surgery, surgeons remove the prostate gland via an incision below the belly button.

24 Sep 2009

Palmetto GBA-TrailBlazer Health cover Renessa treatment of female SUI

Novasys Medical, Inc., a developer of innovative therapies in women's health, announced today that Palmetto GBA and TrailBlazer Health Enterprises, LLC -- two large regional Medicare carriers serving over 10.2 million beneficiaries in California, Nevada, Hawaii, Texas, Oklahoma, Colorado, New Mexico and Virginia -- have agreed to cover the Renessa(R) treatment for female SUI (stress urinary incontinence) in appropriately selected patients with documented medical necessity.

24 Sep 2009

Women usually tightlipped about bladder problems

Women may be known as the more talkative sex, but when it comes to a certain sensitive health topic, their lips are sealed, according to a new "Bladder Talk" survey of 780 women aged 35 and older in North America (U.S. and Canada) sponsored by TENA(R), the worldwide leader in the management of bladder protection, and conducted by Harris Interactive.

24 Sep 2009

FemSoft from Rochester Medical included in the UK Drug Tariff

Rochester Medical Corporation (Nasdaq: ROCM) today announced that the Company's FemSoft(R) Insert has been approved for inclusion in Part IX of the UK Drug Tariff as a prescription product which is reimbursable.

22 Sep 2009

Interim trading update for third quarter of 2009 from Q-Med

In order to ensure that shareholders have up to date information, Q-Med (STO:QMED) has deemed it appropriate to provide an interim trading update for the third quarter of 2009. However, it should be noted that there remains a high degree of uncertainty given the current economic environment.

18 Sep 2009

Results of American Medical Systems Holdings' exchange offer announced

American Medical Systems Holdings, Inc. (NASDAQ: AMMD) (the “Company”), today announced the results of its exchange offer (the “Exchange Offer”) in which the Company offered $1,000 principal amount of its newly issued 4.00% Convertible Senior Subordinated Notes due 2041 (the “2041 Notes”) in exchange for each $1,000 principal amount of its outstanding 3.25% Convertible Senior Subordinated Notes due 2036 (the “2036 Notes”), for up to $250 million, and no less than $100 million, aggregate principal amount of 2036 Notes.

18 Sep 2009

Workshop to educate women on urinary incontinence

UCSF and the National Association For Continence (NAFC) are holding a public workshop on October 3 to help women understand how they can control and treat incontinence.

17 Sep 2009

Sage Products and EngagementHealth partner to launch health promotion programs

Sage Products, Inc. an established innovator in the manufacture of healthcare products and EngagementHealth, LLC, announced today the successful launch of comprehensive disease prevention and health promotion programs. All employees and spouses at Sage Products were invited to participate in the EngagementHealth's biometric screenings, health counseling calls, and individualized targeted risk programs.

15 Sep 2009

Innovative treatments for bowel dysfunction

Twenty percent of all Albertans are plagued by symptoms of diarrhea, constipation, abdominal pain, bloating, and gas. More than an inconvenience for many, these problems are rarely discussed in public, leaving sufferers feeling isolated. Yet bowel symptoms can be disabling, greatly impairing quality of life.

15 Sep 2009

Boston Scientific to market Bladder Health Network's female urodynamic testing solutions in the U.S.

Boston Scientific Corporation (NYSE: BSX) today announced that it has entered into a co-marketing agreement with Bladder Health Network, a privately held company offering advanced testing solutions for urinary incontinence. Bladder Health Network offers an integrated diagnostic service that combines staffing, equipment, supplies and results analysis, helping to ensure that physicians and their patients have access to testing, interpretation and treatment options for urinary incontinence and other problems related to the urinary system.

14 Sep 2009

Urodynamix Technologies raises funds through private placement

Urodynamix Technologies Ltd. (TSX VENTURE:URO) is pleased to announce that it is raising a minimum of $1,500,000 through the issuance of 30,000,000 common shares of the Company at a price of $0.05 per common share. BC Advantage Funds has provided the Company with a lead order of $750,000.

14 Sep 2009

Merck update on the status of telcagepant clinical development programs

Merck & Co., Inc. today updated the status of the clinical development programs for telcagepant (MK-0974) and MK-3207, the Company's investigational oral calcitonin gene-related peptide (CGRP) receptor antagonists for the intermittent treatment of acute migraine.

11 Sep 2009

Protox' Phase 2 study of PRX302 for treating BPH provides positive results

Protox Therapeutics Inc. (TSX: PRX), a leader in the development of receptor targeted fusion proteins, today announced positive 12 month data from its open-label Phase 2 study of PRX302 in males with moderate to severe benign prostatic hyperplasia (BPH). The study results indicate that those patients who received an optimal dose of PRX302 continued to demonstrate significant symptomatic relief at 12 months following a single treatment.

10 Sep 2009

Prostate cancer treatment options discussed in a study

A new study in the Journal of the American Medical Association (JAMA) appears to support the theory outlined in earlier studies that men with more advanced forms of prostate cancer don't benefit from a combination of hormone and radiation therapy.

9 Sep 2009

Incontinence News and Research

Latest Incontinence News and Research

AMS’ products restore patient's pelvic health and their quality of life

Effective decision support tools may help decide whether or not to undertake PSA screening

Urodynamix closes $1.5 million non-brokered private placement for common shares

Quintiles Transnational enter into marketing agreement with Allergan for SANCTURA XR

Initial clinical results for Mpathy Medical's Omnisure sling released

NHSSC awards contract to AMS to supply SUI treatment devices in UK

Study compares benefits of laparoscopic and traditional open surgery for prostate cancer

Palmetto GBA-TrailBlazer Health cover Renessa treatment of female SUI

Women usually tightlipped about bladder problems

FemSoft from Rochester Medical included in the UK Drug Tariff

Interim trading update for third quarter of 2009 from Q-Med

Results of American Medical Systems Holdings' exchange offer announced

Workshop to educate women on urinary incontinence

Sage Products and EngagementHealth partner to launch health promotion programs

Innovative treatments for bowel dysfunction

Boston Scientific to market Bladder Health Network's female urodynamic testing solutions in the U.S.

Urodynamix Technologies raises funds through private placement

Merck update on the status of telcagepant clinical development programs

Protox' Phase 2 study of PRX302 for treating BPH provides positive results

Prostate cancer treatment options discussed in a study

The future of automation: Machine learning–driven hepatocyte and organoid counting

From street to lab: Advancing controlled substance testing with handheld Raman and FTIR

Reimagining light scattering for biotherapeutics

Incontinence News and Research

Latest Incontinence News and Research

The future of automation: Machine learning–driven hepatocyte and organoid counting

From street to lab: Advancing controlled substance testing with handheld Raman and FTIR

Reimagining light scattering for biotherapeutics

Newsletters you may be interested in